VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 300 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2017. The put-call ratio across all filers is 2.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $2,779,000 | -18.5% | 193,908 | -1.6% | 0.04% | -23.1% |
| Q2 2017 | $3,408,000 | +44.3% | 197,010 | -7.9% | 0.05% | +30.0% |
| Q1 2017 | $2,361,000 | -24.0% | 214,021 | 0.0% | 0.04% | -33.3% |
| Q4 2016 | $3,108,000 | -43.6% | 214,021 | -4.7% | 0.06% | -38.1% |
| Q3 2016 | $5,511,000 | +69.5% | 224,461 | +39.0% | 0.10% | +56.5% |
| Q2 2016 | $3,252,000 | -23.4% | 161,461 | 0.0% | 0.06% | -24.4% |
| Q1 2016 | $4,246,000 | -74.1% | 161,461 | 0.0% | 0.08% | -71.4% |
| Q4 2015 | $16,413,000 | -35.3% | 161,461 | +13.5% | 0.29% | -32.8% |
| Q3 2015 | $25,377,000 | -60.9% | 142,261 | -51.3% | 0.43% | -8.0% |
| Q2 2015 | $64,850,000 | +148.9% | 291,922 | +122.6% | 0.46% | +24.7% |
| Q1 2015 | $26,051,000 | +34.9% | 131,161 | -2.8% | 0.37% | +30.5% |
| Q4 2014 | $19,314,000 | -13.6% | 134,961 | -20.8% | 0.28% | -13.1% |
| Q3 2014 | $22,354,000 | – | 170,381 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |